WSBC 35.45 Wesbanco Inc $WSBC Hit a 52 week high of 35.53

New Post Public Reply Private Reply Replies (0) Message Board

Nov 13, 2014 at 2:30 PM

WSBC 35.45 Wesbanco Inc $WSBC Hit a 52 week high of 35.53 Closing the day 09:45 at 35.45 -0.16 -0.45% With a day low of 35.16 and a total volume of 6,198.

WSBC Recent Posts: http://investorshangout.com/Wesbanco-WSBC-55911/

WSBC Wesbanco Inc Recent Headline News

Downgrade Alert for WesBanco (WSBC)
Comtex SmarTrend(R) - Mon Nov 10, 7:58AM CST
WesBanco (NASDAQ:WSBC) was downgraded from Outperform to Market Perform at Keefe Bruyette today. The stock closed yesterday at $34.41 on volume of 79,000 shares, below average daily volume of 95,000. WesBanco, Inc. is a multi-bank holding company. The Company, through its subsidiaries, conducts general, commercial, and mortgage banking, as well as a trust business. WesBanco provides its services to commercial, consumer, and government customers through offices located in West Virginia and eastern Ohio.
WSBC: 35.08 (-0.53)

INVESTOR ALERT: The Law Offices of Vincent Wong Investigates the Board of Directors of ESB Financial Corp. Regarding the Fairness of the Sale of the Company to WesBanco Inc. - ESBF
Business Wire - Wed Nov 05, 12:43PM CST
The Law Offices of Vincent Wong are investigating potential claims against the Board of Directors of ESB Financial Corp. (NasdaqGS:ESBF) ("ESB"

in connection with the sale of the Company to WesBanco Inc. (NasdaqGS:WSBC) ("WesBanco"

.
ESBF: 18.97 (-0.30), WSBC: 35.08 (-0.53)

ESB FINANCIAL CORPORATION SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout
PR Newswire - Wed Nov 05, 12:41PM CST
Rigrodsky & Long, P.A.:
ESBF: 18.97 (-0.30), WSBC: 35.08 (-0.53)

SHAREHOLDER ALERT: Brower Piven Launches An Investigation Into The Proposed Merger Of ESB Financial Corp. With WesBanco Inc. And Encourages Investors To Contact The Firm For Additional Information
Business Wire - Tue Nov 04, 5:21PM CST
The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by the Board of Directors of ESB Financial Corp. ("ESB" or the "Company"

(Nasdaq: ESBF) relating to the proposed buyout of the Company by WesBanco Inc. ("WesBanco"

.
ESBF: 18.97 (-0.30), WSBC: 35.08 (-0.53)

INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Investors of ESB Financial Corp. of Investigation of the Board of Directors of the Company Regarding the Fairness of the Sale of the Company to WesBanco Inc.
Business Wire - Mon Nov 03, 3:03PM CST
Levi & Korsinsky is investigating the Board of Directors of ESB Financial Corp. ("ESB" or "the Company"

(NasdaqGS:ESBF) for possible breaches of fiduciary duty and other violations of state law in connection with the sale of the Company to WesBanco Inc. (NasdaqGS:WSBC).
ESBF: 18.97 (-0.30), WSBC: 35.08 (-0.53)

Merger Arbitrage Mondays - November 3, 2014
Asif Suria - Seeking Alpha - Mon Nov 03, 12:35PM CST
Merger Activity increased last week with five new mergers announced. None of the pending deals closed last week. You can find all the active deals listed below in our Merger Arbitrage Tool that automatically updates itself during market hours. ...
ESBF: 18.97 (-0.30), AVIV: 33.36 (+0.16), ACMP: 62.10 (+0.36), CPWR: 10.17 (-0.02), WSBC: 35.08 (-0.53), CQB: 14.45 (+0.01), OHI: 37.90 (+0.11), TRNX: 26.38 (+0.27), WMGIZ: 4.43 (+0.03), COVS: 2.79 (unch), WPZ: 51.46 (+0.28)

ESB FINANCIAL CORP. INVESTOR ALERT: Faruqi & Faruqi, LLP Announces the Investigation of ESB Financial Corp. (ESBF) Over the Proposed Sale of the Company to WesBanco, Inc.
PR Newswire - Fri Oct 31, 6:20PM CDT
Juan E. Monteverde, a partner at Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of ESB Financial Corp. ("ESB" or the "Company"

(Nasdaq: ESBF) for potential breaches of fiduciary duties in connection with the sale of the Company to WesBanco, Inc. ("WesBanco"

(WSBC) for approximately $324.40 million. The Company's stockholders will receive .502 shares of WesBanco and $1.76 for each share of ESB common stock they own.
ESBF: 18.97 (-0.30), WSBC: 35.08 (-0.53)

SHAREHOLDER ALERT: Brodsky & Smith, LLC Announces Investigation of ESB Financial Corp. in Connection with the Sale of the Company
Business Wire - Fri Oct 31, 5:35PM CDT
Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of ESB Financial Corp. ("ESB Financial" or the "Company"

(Nasdaq: ESBF) relating to the proposed acquisition by WesBanco Inc. ("WesBanco"

.
ESBF: 18.97 (-0.30), WSBC: 35.08 (-0.53)

ESBF INVESTOR ALERT: Levi & Korsinsky, LLP Launches Investigation of the Board of Directors of ESB Financial Corp. Regarding the Fairness of the Sale of the Company to WesBanco Inc. -- ESBF
PR Newswire - Fri Oct 31, 10:09AM CDT
Levi & Korsinsky is investigating the Board of Directors of ESB Financial Corp. ("ESB" or "the Company"

(NasdaqGS: ESBF) for possible breaches of fiduciary duty and other violations of state law in connection with the sale of the Company to WesBanco Inc. (NasdaqGS: WSBC).
ESBF: 18.97 (-0.30), WSBC: 35.08 (-0.53)

WesBanco's (WSBC) CEO Announces Agreement and Plan of Merger with ESB Financial Corporation (Transcript)
SA Transcripts - at Seeking Alpha - Fri Oct 31, 9:25AM CDT

WSBC: 35.08 (-0.53)

SHAREHOLDER ALERT: Brodsky & Smith, LLC Announces Investigation of ESB Financial Corp. in Connection with the Sale of the Company -ESBF
PR Newswire - Thu Oct 30, 3:50PM CDT
Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of ESB Financial Corp. ("ESB Financial" or the "Company"

(Nasdaq -ESBF-News) relating to the proposed acquisition by WesBanco Inc. ("WesBanco"

.
ESBF: 18.97 (-0.30), WSBC: 35.08 (-0.53)

INVESTOR ALERT: Levi & Korsinsky, LLP Launches Investigation of the Board of Directors of ESB Financial Corp. Regarding the Fairness of the Sale of the Company to WesBanco Inc.
Business Wire - Thu Oct 30, 2:10PM CDT
Levi & Korsinsky is investigating the Board of Directors of ESB Financial Corp. ("ESB" or "the Company"

(NasdaqGS:ESBF) for possible breaches of fiduciary duty and other violations of state law in connection with the sale of the Company to WesBanco Inc. (NasdaqGS:WSBC).
ESBF: 18.97 (-0.30), WSBC: 35.08 (-0.53)

EQUITY ALERT: The Rosen Law Firm Announces Investigation of ESB Financial Corp. Concerning its Proposed Sale to WesBanco Inc. - ESBF
Business Wire - Thu Oct 30, 12:21PM CDT
The Rosen Law Firm, P.A. announces that it is investigating the Board of Directors of ESB Financial Corp. (NASDAQ: ESBF) for possible breaches of fiduciary duty and other violations of law by failing to adequately shop ESB Financial to maximize shareholder value before agreeing to be acquired by WesBanco Inc. (NASDAQ: WSBC).
ESBF: 18.97 (-0.30), WSBC: 35.08 (-0.53)

WesBanco, Inc. Furthers Expansion into Pittsburgh Market; Announces Agreement and Plan of Merger with ESB Financial Corporation
Business Wire - Wed Oct 29, 4:09PM CDT
WesBanco, Inc. ("WesBanco"

(Nasdaq:WSBC) and ESB Financial Corporation ("ESB"

(Nasdaq:ESBF) jointly announced today that they have executed a definitive Agreement and Plan of Merger providing for the merger of ESB with and into WesBanco. James C. Gardill, Chairman of the Board, and Todd F. Clossin, President & CEO, of WesBanco and William B. Salsgiver, Chairman of the Board, and Charlotte A. Zuschlag, President & CEO, of ESB, made the joint announcement.
ESBF: 18.97 (-0.30), WSBC: 35.08 (-0.53)

WesBanco Has Returned 10.7% Since SmarTrend Recommendation (WSBC)
Comtex SmarTrend(R) - Wed Oct 29, 9:59AM CDT
SmarTrend identified an Uptrend for WesBanco (NASDAQ:WSBC) on August 25th, 2014 at $31.36. In approximately 2 months, WesBanco has returned 10.65% as of today's recent price of $34.70.
WSBC: 35.08 (-0.53)

WesBanco's (WSBC) CEO Todd Clossin on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Wed Oct 22, 3:40PM CDT

WSBC: 35.08 (-0.53)

WesBanco Announces 17% Increase in Third Quarter Net Income
PR Newswire - Tue Oct 21, 3:05PM CDT
Todd F. Clossin, President and Chief Executive Officer of WesBanco, Inc. (NASDAQ Global Market: WSBC), a Wheeling, West Virginia based multi-state bank holding company, today announced an increase in net income and related earnings per share for the three and nine months ended September 30, 2014.
WSBC: 35.08 (-0.53)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

PANDAG G1 Debuts: Revolutionizing Lawn Care Efficiency

The Future of Landscaping Unveiled Get this—PANDAG is set to shake things up at GaLaBau 2026 with their futuristic G1 autonomous mower. This isn't just another piece of lawn equipment; it's practically a tech marvel on wheels, weaving together LiDAR, AI Vision, RTK, and 4G tech to make it the ultimate multitasker for the landscaping industry. We're talking obstacle...

GORGIE Unleashes Berry Burst: Target's New Drink Star

GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...

Surfing Dogs Ride Waves, Support Orphan Pets

Waves, Paws, and Passion Who would've thought that dogs catching waves could also catch hearts and wallets? Well, that's exactly what's happening today at Del Mar Dog Beach with the 21st Annual Surf Dog Surf-A-Thon revving up the excitement. It's a sun-soaked day in Rancho Santa Fe, California, right in the thick of things at the longest-running dog surf competition. For...

UWM Faces Class Action Deadline: Key Insights for Investors

The High Stakes Reality for UWM Investors If there's one thing that's certain in this jittery world of investing, it's that losses have a way of waking you up. Right now, anyone tied up with UWM Holdings Corporation (NYSE: UWMC) shares needs to keep their wits about them; we're barreling toward an October 13, 2026 deadline for a class action lawsuit. The clock's ticking...

Tam-Peli Steps Up in SCLC Battle: Trial Insights

Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...

Ris-Rez May Set New Standard in Relapsed SCLC

The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...

PwC US and India Unite for Global Consultancy Powerhouse

Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...

Regeneron Faces Legal Heat: Lead Plaintiff Deadline Looms

Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...

MRI Surveillance Gains Ground in Lung Cancer Care

Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....

Trial Disappointment: No Significant Gains in NSCLC

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...